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SD) after 1 week, to 16.63 % (±5.4 % SD, p < 0.0001) 
after 1 month, to 17.08 % (±4.6 % SD, p < 0.0001) after 
3 months and to 15.94 % (±5.4 % SD, p < 0.0001) after 
6 months. CD31+/CD42b−, CD31+/Annexin+/− EMP 
remained unchanged. CD31+/CD41b+ PMP evidenced 
a slight, but statistically significant increase after TAVI 
and remained elevated during the entire follow-up. Apart 
from a procedure-related improvement in echocardio-
graphic parameters, TAVI procedure led also to a decline 
in CD62E+ EMP. The reduction in pressure gradients with 
less hemodynamic shear stress seems also to have benefi-
cially affected endothelial homeostasis.
Keywords Endothelial microparticles · Platelet 
microparticles · Endothelial dysfunction · TAVI ·  
Aortic stenosis
Introduction
Degenerative aortic stenosis (AS) is the most frequent 
form of acquired valvular heart disease worldwide and its 
prevalence is expected to further increase within the aging 
population. Although the majority of patients have only 
mild valve disease, about 5 % develop severe AS [1–3]. 
Morbidity and mortality rates are considerably high among 
patients not undergoing valve replacement. Once symp-
toms occur in these patients, the mortality rate is approxi-
mately 50 % over the next 3 years [4].
Pathophysiology of aortic stenosis can be characterized 
by multiple steps: inflammation, fibrosis and finally calci-
fication. It is not completely understood whether inflam-
mation in aortic stenosis is a response to tissue injury or 
if aortic stenosis might be primarily an inflammatory dis-
ease. From the literature we know that pro-inflammatory 
Abstract Degenerative aortic stenosis (AS) is the most fre-
quent form of acquired valvular heart disease. AS is known 
to entail endothelial dysfunction caused by increased 
mechanical shear stress leading to elevated circulatory 
levels of microparticles. Endothelial and platelet micro-
particles (EMP and PMP) are small vesicles that originate 
from activated cells and thrombocytes. We sought to evalu-
ate whether transcatheter aortic valve implantation (TAVI) 
procedure would elicit effects on circulating EMP and 
PMP. 92 patients undergoing TAVI procedure for severe 
AS were included in this study. Samples were obtained at 
each visit before TAVI, 1 week post-procedure and at 1, 3 
and after 6 months after TAVI and were evaluated using 
flow cytometry. A 12 month clinical follow-up was also 
performed. CD62E+ EMP concentration before TAVI was 
21.11 % (±6.6 % SD) and declined to 20.99 % (±6.8 % 
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markers such as Tumor necrosis factor-alpha (TNF-alpha), 
receptor activator of nuclear factor-kappa B (NF-κB) ligand 
(RANKL) and Interleukin-6 (IL-6) are associated with 
aortic stenosis [5–8]. Also elevated plasma levels of low-
density lipoprotein cholesterol were associated with an 
augmented aortic valve calcium deposition and a higher 
incidence of aortic stenosis [9].
As there is no medical treatment for aortic stenosis 
besides vasodilators and diuretics for acute decompen-
sation, the mainstay of treatment for aortic stenosis is 
still surgical or interventional aortic valve replacement 
[6, 10]. Ongoing inflammation in the circulatory system 
and increased shear stress has also been associated with 
endothelial dysfunction [11, 12]. Over the last few years, 
microparticles have come more and more into the focus of 
clinical scientists as they can serve as parameters to deter-
mine and monitor vascular dysfunction in several disease 
conditions [12–16].
Microparticles are defined as small phospholipid vesi-
cles without a nucleus that are released from different 
cells, platelets, erythrocytes, leukocytes and endothelial 
cells [17–19]. Endothelial cell microparticles (EMP) can 
be identified by antigens expressed by mature endothelial 
cells such as CD31 [20]. EMP concentrations are known to 
reflect endothelial dysfunction as there are strong associa-
tions between increased circulating EMPs and both struc-
tural and functional abnormalities [21, 22]. Microparticles 
derived from platelets (PMP) are identified by the expres-
sion of platelet markers such as CD41 or CD61 [23]. High 
levels of PMPs are known to be strongly associated with 
thrombotic complications [24]. Horn et al. have recently 
shown that EMPs decrease 3 months after transcath-
eter aortic valve implantation (TAVI), reflecting improved 
endothelial function and wall shear stress [25].
The main focus of our study was to further extend our 
knowledge about microparticles in AS and patients under-
going TAVI. We sought to evaluate whether TAVI pro-
cedure could lead to an alteration or possible decrease in 
circulating levels of both endothelial and platelet micropar-
ticles epitomizing an improvement in vascular integrity and 
function after 1, 3 and 6 months indicating a possible long-
term beneficial effect of interventional aortic valve replace-
ment on overall endothelial function.
Methods
The study protocol was approved by the Ethics Commit-
tee of the Friedrich-Schiller-University, Jena, Germany. 
The study was conducted according to the principles of 
the Declaration of Helsinki and Good Clinical Practice and 
informed consent was obtained from all patients before 
being enrolled.
Study protocol
A total of 92 patients suffering from symptomatic severe AS 
admitted to our clinic for TAVI were enrolled in this study 
between November 2011 and February 2014. The diagnosis 
of severe AS was defined according to the guidelines of the 
European Society of Cardiology. Mean and peak pressure 
gradients (MPG and PPG), maximum velocity (Vmax) and 
aortic valve area were assessed by transthoracic echocardi-
ography by experienced sonographers in our echo lab. All 
patients underwent pre-interventional screening with ECG, 
laboratory parameters, transthoracic and transesophageal 
echocardiography and coronary angiography. The obtained 
results were discussed in the interdisciplinary heart team. 
Patients that were considered not eligible for operative aor-
tic valve replacement were planned for TAVI procedure.
TAVI procedure was performed via transfemoral access 
in 77 patients and via a transapical approach in 15 patients. 
In patients undergoing transfemoral TAVI, a 14–21 French 
delivery sheath was inserted in the femoral artery, depend-
ing on the size and type of TAVI-device. In patients without 
a permanent pacemaker, a temporary transcutaneous pace-
maker was placed via transjugular access for periproce-
dural rapid pacing. A balloon valvuloplasty was performed 
during rapid pacing. Subsequently, implantation of the 
valve prosthesis (Edwards Sapien XT, n = 64; Corevalve, 
n = 11; JenaValve, n = 13; SJM Portico, n = 4) was per-
formed. Using a closure device (Proglide; Abbott USA) the 
artery access was closed. For the transapical approach, an 
anterolateral mini-thoracotomy was performed to obtain 
optimal access to the apex of the left ventricle followed 
by pericardiotomy. The left ventricular apex was punc-
tured with a standard access needle and an access wire was 
inserted. Then, a 12 French sheath was placed in the apex 
for ventricular access. Next, a balloon valvuloplasty was 
performed during rapid pacing. The valve was then intro-
duced over the sheath and placed in the right position under 
angiographic control. The pharmacological regimen after 
TAVI in our clinic comprised of 100 mg of acetylsalicylic 
acid and 75 mg of clopidogrel for 3 months which was fol-
lowed by a monotherapy of 100 mg of acetylsalicylic acid.
Plasma samples were obtained from all enrolled patients 
on the day of the procedure and 1 week post-procedure and 
at each of the follow-up visits after 1, 3 and 6 months.
Flow cytometry
Microparticles in the collected blood samples were 
stained with antibodies against CD31, CD42b, CD62E 
and Annexin to analyze circulatory levels of CD31+/
Annexin+, CD31+/Annexin−, microparticles using flow 
cytometry. EMP were defined as CD31+/CD42b− and 
PMP as CD31+/CD42b+.
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According to previous studies [13, 18, 26], samples 
were centrifuged for 10 min at 2000g. For the prepara-
tion of platelet-poor plasma, the plasmatic supernatant was 
obtained without disturbing the buffy coat. Fifty microlit-
ers of platelet-poor plasma was incubated for 20 min with 
labeled antibodies: 4 µl of anti-CD31-PE (BD Pharmigen, 
USA), anti-CD62-FITC (Ancell Corporation, USA), anti-
CD42b-Cy5 (BD Pharmigen, USA) and anti-Annexin-V-
APC (BD Pharmigen, USA) or matching isotype controls 
(all from BD Pharmigen, USA). In the next step, samples 
were then diluted with 1 ml of phosphate-buffered saline 
(PBS) and analyzed on a flow cytometer (FACS Calibur, 
BD Biosciences, USA).
To determine the size of the acquired events, size cali-
bration beads were added to the samples (Molecular 
Probes, Invitrogen, USA). MP were defined as particles 
that were smaller than 1.5 µm. MP were expressed as per-
centage of events in the relevant gate. The obtained data 
were processed using CellQuest Pro software (BD Bio-
sciences, USA).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
software (GraphPad Software, La Jolla, USA). All data are 
given as mean ± standard deviation (SD) or median with 
interquartile range (IQR). The Wilcoxon’s matched pairs 
and the paired t-test were utilized to calculate significances 
between the groups. p values <0.05 were considered statis-
tically significant. Bonferroni-Holm correction was used to 
adjust p values for multiple testing. * indicates a p of <0.05, 
** a p of <0.01 and *** a p of <0.001.
Results
The characteristics of the study population are presented in 
Table 1. 92 patients with a mean age of 80.0 ± 7.13 years 
were included in the study and were followed-up over a 
period of 6 month after TAVI with periodical blood with-
drawals for EMP and PMP analysis. At 12 month post-
TAVI, a clinical follow-up was performed. Four different 
valve types were used (Edwards Sapien XT n = 64, Cor-
evalve n = 11, JenaValve n = 13, SJM Portico n = 4). 
Follow-up time points with measurement of micropar-
ticles were prior to TAVI and 1 week post-TAVI and at 1, 
3 and 6 months after TAVI (see Fig. 1). Mean EuroScore 
was 23.1 ± 14.5. TAVI procedure was performed via trans-
femoral access in 77 patients, whereas in 15 patients the 
valve was implanted via a transapical approach. None of 
the patients died within the 30 days after TAVI, though, five 
patients died within the 12 months follow-up period (mor-
tality rate 5.4 %). Complication rates defined using VARC-2 
criteria are also stated in Table 1 [27]. In total, six patients 
evidenced neurological deficit after TAVI (stroke n = 3, 
TIA n = 3). Acute kidney injury according to VARC-2 cri-
teria occurred in two patients (stage 1 n = 1, stage 2 n = 1). 
Minor bleeding complications (vascular site hematoma, 
transfusion of <2 red blood cell concentrates) according to 
VARC-2 criteria occurred in 16 patients (17.4 %), major 
bleeding complications (transfusion of ≥2 red blood cell 
concentrates) in 24 patients (26.1 %) and relevant vascular 
access-related complications (dissection, pseudoaneurysm) 
in 8 patients (8.7 %). Implantation of a permanent pace-
maker was necessary within 72 h in 5 patients (5.4 %). Per-
manent pacemaker implantation was performed in 13 % of 
patients after TAVI procedure, these data are comparable 
with previously published results [28]. Conversion to open 
surgery due valve malpositioning was necessary in 1 patient. 
Forty patients (43.5 %) were free of post-procedural aortic 
insufficiency, grade 0–1 (trace) aortic insufficiency was pre-
sent in 21 patients (22.8 %), grade 1 in 29 patients (31.5 %) 
and ≥grade 2 only in 1 patient (1.1 %). Clinical and func-
tional results after TAVI procedure were good as shown by 
significantly reduced Vmax, MPG and PPG (p < 0.001). Also 
a slight improvement in ejection fraction was documented 
during follow-up, from 55.9 % (±18.4 SD) before TAVI to 
62.6 % (±14.3 SD) after 6 months (p < 0.01). A procedure-
related drop in hemoglobin levels from 7.6 mmol/l (±1.1 
SD) to 6.69 (±1.0 SD, p < 0.001) and an increase of CRP 
from 13.9 mg/l (±29.3 SD) to 42.5 mg/l (±29.8, p < 0.001) 
was also over served. However, at later visits levels returned 
to those seen before TAVI procedure. It is of note that cre-
atinine levels did not increase significantly immediately fol-
lowing TAVI procedure, however, during the follow-up a 
rise in creatinine was found (see Table 2, p < 0.01).  
Plasma samples were obtained at each study visit 
and were analyzed for EMP and PMP. EMP were 
defined as CD62E+ and CD31+/CD42− and PMP as 
CD31+CD42b+. Pre TAVI levels of CD31+CD42b− 
EMP correlated with Vmax (r = 0.258, p = 0.016), MPG 
(0.301, p = 0.004) and PPG (0.230, p = 0.032), see Fig. 2. 
No significant correlation was found for CD31+CD42b− 
EMP with aortic valve area (AVA). A correlation analysis 
of all EMP and PMP populations with parameters of aortic 
valve function is shown in supplementary Table 1.
CD62E+ EMP concentration before TAVI was 21.11 % 
(±6.6 % SD) and declined to 20.99 % (±6.8 % SD) after 
1 week, to 16.63 % (±5.4 % SD, p < 0.0001) after 1 month, 
to 17.08 % (±4.6 % SD, p < 0.0001) after 3 months and 
to 15.94 % (±5.4 % SD, p < 0.0001) after 6 months (see 
Fig. 3). No statistically significant differences were found 
for CD31+/CD42− EMP: pre TAVI 0.57 % (±0.45 % SD), 
1 week 0.65 % (±0.45 % SD), 1 month 0.66 % (±0.65 % 
SD), 3 months 0.69 % (±0.76 % SD) and 6 months 0.62 % 
(±0.55 % SD).
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Interestingly, CD31+/CD42+ PMP tended to 
increase over time after TAVI procedure. Base line con-
centration was 0.026 % (±0.0049 % SD), after 1 week 
0.024 % (±0.0038 % SD), 1 month 0.052 % (±0.0080 % 
SD, p = 0.0003), 3 months 0.060 % (±0.0101 % SD, 
p < 0.0001) and 6 months 0.66 % (±0.0100 % SD, 
p < 0.0001).
We also analyzed CD31+/Annexin+ and CD31+/
Annexin− EMP. Statistically significant differences 
were found neither for CD31+/Annexin+ nor CD31+/
Annexin− EMP. The basic mean level before TAVI for 
CD31+/Annexin+ EMP was 0.022 % (±0.0041 % SD), 
after 1 week 0.021 % (±0.0043 % SD), 1 month 0.022 % 
(±0.0038 % SD), 3 months 0.035 % (±0.0056 % SD) and 
after 6 months 0.031 % (±0.0049 % SD). Similar results 
were found for CD31+/Annexin− EMP. Mean concentra-
tion before TAVI was 0.56 % (±0.048 % SD), after 1 week 
0.64 % (±0.047 % SD), 1 month 0.68 % (±0.071 % SD), 
3 months 0.69 % (±0.086 % SD) and after 6 months 
0.63 % (±0.056 % SD).
No differences were found between valve types or the 
approach that was used (transfemoral or transapical). 
Based on our clinical source data we have performed a 
comprehensive correlation analysis of EMP and PMP data 
points and correlated them to clinical features and also 
complications (using VARC-2 criteria) and valve types. 
Unfortunately and likely due to the small sample size in 
sub-groups we have not found any relevant correlations. 
When performing Bonferroni-Holm correction for mul-
tiple testing, no statistically significant correlations were 
found.




Age (years) 80.0 ± 7.13
Height (cm) 163.4 ± 9.3
Weight (kg) 76.9 ± 13.3
NYHA stage 2.75 ± 1.38
Euroscore 23.1 ± 14.5
Total (%)
Diabetes 42 (45.6 %)
Arterial hypertension 82 (89.1 %)
Coronary artery disease 68 (73.9 %)
 One vessel disease 21 (22.8 %)
 Two vessel disease 9 (9.8 %)
 Three vessel disease 19 (20.6 %)
Myocardial infarction 12 (13.0 %)
Atrial fibrillation 5 (5.4 %)
Stroke 9 (9.8 %)
Peripheral artery disease 20 (21.7 %)
COPD 20 (21.7 %)
Laboratory parameters Median (IQR)
Creatinine (µmol/l) 95.5 (74.0–123.8)
GFR (ml/min) 59.2 (41.4–60.0)
C-reactive protein (mg/l) 4.9 (2.0–11.1)
BNP (pg/ml) 340.5 (180.3–814.0)
Hemoglobin (mmol/l) 7.5 (7.0–8.2)
Hematokrit 0.36 (0.34–0.40)
Troponin I (ng/ml) 0.04 (0.028–0.11)
Creatinine kinase (U/l) 1.25 (0.98–1.94)
Valve parameters Total
Transfemoral access 77 (83.7 %)
Transapical access 15 (16.3 %)
 Edwards Sapien XT 64 (69.6 %)
 Corevalve 11 (11.9 %)
 JenaValve 13 (14.2 %)
 SJM Portico 4 (4.3 %)
 Valve size (mm) 26.3 ± 2.24
Complications Total
Stroke 3 (3.3 %)
TIA 3 (3.3 %)
Acute kidney injury
 Stage 1 1 (1.1 %)
 Stage 2 1 (1.1 %)
 Stage 3 0 (0.0 %)
Vascular comlications Total
Minor bleeding 16 (17.4 %)
Table 1  continued
Vascular comlications Total
Major bleeding 24 (26.1 %)
Life-threatening bleeding 0 (0.0 %)
Access-related complications 8 (8.7 %)
Patients requiring transfusions 28 (30.4 %)
Mean number of tranfusions 2.6
New pacemaker requirement (72 h) 5 (5.4 %)
New pacemaker requirement (7d) 12 (13.0 %)
Conversion to open surgery 1 (1.1 %)
Valve malpositioning 1 (1.1 %)
Post-procedural aortic insufficiency
 None 40 (43.5 %)
 Grade 0–1 (trace) 21 (22.8 %)
 Grade 1 29 (31.5 %)
 ≥Grade 2 1 (1.1 %)
ICU treatment (h) 26.0 
(23.0–47.8)
462 Heart Vessels (2017) 32:458–466
1 3
Discussion
Previous studies have confirmed that elevated levels of 
microparticles are associated with progression of car-
diovascular disease [29]. It was shown that high levels of 
CD62E+ EMPs are associated with a worse outcome and 
higher rates of hospitalization in patients with stroke his-
tory [30]. Dehl et al. demonstrated in 2008 that EMP and 
PMP are elevated in the plasma of patients with severe aor-
tic stenosis [31]. More recently, Horn et al. provided evi-
dence that TAVI procedure reduces the number of circulat-
ing CD31+/CD42b− and CD62E+ EMP [25].
Here, in this study we sought to investigate the role 
of CD62E, CD31+/CD42b−, CD31+/Annexin+ and 
CD31+/Annexin− EMP and CD31+/CD42b+ PMP in 
patients with severe aortic stenosis undergoing TAVI over a 
longer follow-up period of 6 months. Regarding functional 
parameters of aortic stenosis, we found a significant cor-
relation of CD31+/CD41b− but not CD62E+ EMP with 
Vmax, MPG and PPG. Interestingly, no correlation was 
found for EMP levels with aortic valve area. This could 
be related to the fact the parameters for Vmax, MPG and 
PPG evidenced a greater statistical spread compared to 
AVA. Due the definition of aortic stenosis, AVA values are 
within a rather narrow range (between approximately 0.5 
and 1.0 cm2). It is known that EMP are released upon shear 
stress from activated endothelial cells [20, 32]. In patients 
with severe aortic stenosis, vascular shear stress is con-
stantly elevated leading to an increased expression of adhe-
sion molecule expression [33, 34]. It was speculated that 
this pathophysiologic process could lead to further progres-
sion of valve calcification and dysfunction.
The main focus of our study was to evaluate whether 
TAVI procedure could lead to alteration or possible 
decrease in circulating levels of microparticles epitomiz-
ing an improvement in vascular integrity and function. We 
observed that after TAVI a significant decline in CD62E+ 
EMP occurs as evidenced at follow-up visits at 1, 3 and 
6 months (Fig. 2a). Horn et al. already have verified that 
TAVI can reduce systemic levels of EMP. It was possible 
to corroborate these data in a larger cohort with a longer 
follow-up and show that CD62E+ levels remained low 
over the whole follow-up period of 6 months. In contrast to 
the results by Horn et al., however, plasma concentration of 
CD31+/CD42b− EMP remained at baseline level at every 
visit after TAVI procedure (Fig. 2b).
Of special interest was the finding that PMP staining 
positive for CD31+/CD42b+ increased significantly over 
time after TAVI (Fig. 2c). In the study conducted by Horn 
et al. no changes in CD31+/CD42b+ PMP levels were 
recorded after TAVI procedure. In an experimental study by 
Franca et al. it was shown that PMP levels were not affected 
by the administration of clopidogrel over a surveillance 
period of 3 weeks [35]. We can only hypothesize that pos-
sible surface interaction effects of platelets and the newly 
implanted valve could have influenced the generation of 
PMP. In addition, CD31+/CD42b+ PMP levels might also 
be a surrogate parameter for beginning thrombus formation 
on cusps of the newly implanted valve [36, 37]. However, 
this remains truly speculative and further studies would be 
warranted to further elucidate the mechanism behind.
In the progression of cardiovascular disease and 
increased endothelial dysfunction and damage, apop-
tosis can be triggered leading to the release of CD31+/
Annexin+ EMP. The group of Sinning et al. demonstrated 
that heightened levels of CD31+/Annexin+ EMP are 
related to significantly increase cardiovascular mortality, 
need for revascularization and major adverse cardiovascular 
events [38]. In our study, levels of CD31+/Annexin+ EMP 
did not evidence any differences during follow-up. One 
could speculate that TAVI leads to a halt in the progression 
of endothelial stress and dysfunction as CD31+/Annexin+ 
did not increase and CD62E+ EMP decreased over time. 
However, further prospective studies with longer follow-up 
are needed to provide evidence for this hypothesis.
As the shedding of microparticles is also associated with 
systemic inflammation and endothelial activation, a vicious 
circle of hemodynamic shear stress and endothelial dys-
function is present in the pathophysiological setting of AS. 
It was shown that inflammation might play a fundamental 
Fig. 1  Flow chart of the study protocol
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part in the progression of degenerative AS. Microparticles 
also seem to play a role as signaling factors within the vas-
cular compartment mediating inflammatory, angiogenesis 
and coagulation [39, 40]. TAVI proved to be a very prom-
ising procedure in considerably improving valvular func-
tion in patients with severe AS. As levels of CD62E+ EMP 
were significantly reduced and other fractions of EMP did 
not increase during follow-up, one could argue that one 
factor for the progression of vascular dysfunction was 
taken out of the equation, thus leading to an improvement 
in endothelial function.
Conclusion
In conclusion, TAVI led not only to a procedure-related 
improvement in hemodynamic parameters, also endothe-
lial dysfunction may have been alleviated by the procedure. 
Table 2  Echocardiographic and laboratory parameter before TAVI and after 1 week and at 1, 3 and 6 months of follow-up
Significances are expressed vs. baseline parameters before TAVI
* Indicates a p of <0.05, ** a p of <0.01 and *** a p of <0.001
n.a data not available
Pre TAVI 1 week 1 month 3 months 6 months
Ejection fraction (%) 55.9 ± 18.4 60.8 ± 12.9* 58.4 ± 16.3 63.2 ± 15.2** 62.6 ± 14.3**
Vmax (m/sec) 4.34 ± 0.7 2.21 ± 0.3*** 2.22 ± 0.5*** 2.17 ± 0.5*** 2.23 ± 0.6***
Mean pressure gradient (mmHg) 46.5 ± 14.8 11.3 ± 6.5*** 11.1 ± 5.4*** 11.1 ± 5.7*** 11.6 ± 6.1***
Peak pressure gradient (mmHg) 77.5 ± 22.7 20.9 ± 11.3*** 20.7 ± 10.8*** 20.4 ± 9.8*** 21.2 ± 11.1***
Aortic valve area (cm2) 0.66 ± 0.18 n.a. n.a. n.a. n.a.
LVEDD (mm) 48.9 ± 7.4 49.8 ± 7.3 49.5 ± 8.2 47.9 ± 6.9 48.3 ± 7.5
LVESD (mm) 31.7 ± 9.4 n.a. n.a. n.a. n.a.
Creatinin (µmol/l) 95.5 (74.0–123.8) 81.5 (67.5–118.8) 93.0 (75.0 to ±128.0) 101.0 (84.0–128.5) 104.5 (81.5–135.3)**
C-reactive protein (mg/l) 4.8 (2.0–11.1) 37.4 (20.0–59.6)*** 4.9 (2.2 to 15.0) 3.4 (2.0–7.9) 3.1 (2.0–5.9)
hemoglobin (mmol/l) 7.5 (7.0–8.2) 6.6 (6.2–7.2)*** 7.3 (6.6 to 8.0)*** 7.6 (6.9–8.5) 7.9 (7.2–8.5)
Fig. 2  Correlation of 
CD31+CD42b− EMP levels 
with parameters of aortic valve 
function. CD31+CD42b− EMP 
evidenced a significant correla-
tion with Vmax, MPG and PPG, 
however, no correlation was 
found with aortic valve area 
(AVA)
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The reduction in transvalvular gradients and less hemody-
namic shear stress seems also to have possible beneficial 
effects on endothelial homeostasis.
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